1243 related articles for article (PubMed ID: 24030703)
1. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
2. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
3. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
4. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
5. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
8. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
9. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
10. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
[TBL] [Abstract][Full Text] [Related]
11. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
[TBL] [Abstract][Full Text] [Related]
12. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
14. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
[TBL] [Abstract][Full Text] [Related]
15. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
[TBL] [Abstract][Full Text] [Related]
20. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ
Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
